Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The 201 Trial in Untreated Parkinson's Disease
Movement Disorders
P9 - Poster Session 9 (8:00 AM-9:00 AM)
3-011
Risvodetinib is an oral, selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl).  In pre-clinical animal models, risvodetinib was shown to halt disease progression and reverse functional loss with substantial reduction of alpha-synuclein aggregate pathology.

To evalute the safety, tolerability and clinical benefit of risvodetinib (IkT-148009) in untreated Parkinson's disease.

Risvodetinib was given once daily at 50, 100 or 200 mg, all believed to be therapeutic doses. 120 patients were randomized 1:1:1:1 across the three doses or placebo for 12 weeks and subsequently rolled into a 12 month extension study with the placebo group moving onto the top therapeutic dose. Safety and tolerability were measured by evaluation of frequency and severity of treatment-emergent adverse events, measures of cardiovascular safety, standard laboratory analyses and monitoring for changes in vision. A hierarchy of 15 secondary endpoints evaluated the potential benefit of risvodetinib on measures of motor and non-motor function in the Central and Enteric Nervous Systems. Biomarker analysis using CSF/plasma assessment by seed-amplification assay and skin biopsy complement functional assessments.

As of this writing the trial is ongoing with 32 participants in consenting, screening or enrolled. 197 potential participants have been identified using a proprietary pre-qualification portal that allows pre-qualified participants to communicate directly with trial sites. By the time this presentation will be made public, it is anticipated that the trial will be fully enrolled and blinded or unblinded data evaluating treatment benefit and safety/tolerability of risvodetinib (IkT-148009) over 12 weeks of once daily dosing will be discussed.

Data from a 12 week double-blinded, placebo controlled trial will be presented providing a first look into whether a treatment validated in models of heritable and sporadic PD can impact disease in human Parkinson's.

Authors/Disclosures
Milton H. Werner (Inhibikase Therapeutics, Inc.)
PRESENTER
No disclosure on file
C. W. Olanow, MD Dr. Olanow has received personal compensation for serving as an employee of Clintrex Research Corporation. Dr. Olanow has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Clintrex Research Corporation. Dr. Olanow has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Chevron/Syngenta. Dr. Olanow has stock in Clintrex Research Corporation.
Andrew J. McGarry, MD (Cooper University Hospital) Dr. McGarry has nothing to disclose.
Christopher Meyer (Inhibikase Therapeutics) No disclosure on file
Emaryn Mancino (Inhibikase Therapeutics) No disclosure on file
Carl Klint (Inhibikase Therapeutics) No disclosure on file
Jacqueline Pellecchia (Inhibikase Therapeautics) No disclosure on file